According to the first report of using autologous G-CSF mobilized CD34+ therapy in acute ischemic stroke patients, CD34+ cells improved modified rankin score (MRS) and national institutes of health stroke score (NIHSS) in the 6-month follow-up (Banerjee et al., 2014). This evidence concerns the gene CSF3 and stroke disorder.